ABBV-637 / AbbVie - LARVOL DELTA

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors (clinicaltrials.gov) - P1 | N=81 | Active, not recruiting | Sponsor: AbbVie | Trial completion date: Aug 2024 ➔ Feb 2025 | Trial primary completion date: Aug 2024 ➔ Feb 2025

Adverse events • Combination therapy • Monotherapy • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors (clinicaltrials.gov) - P1 | N=81 | Active, not recruiting | Sponsor: AbbVie | Trial completion date: Feb 2024 ➔ Aug 2024 | Trial primary completion date: Feb 2024 ➔ Aug 2024

Adverse events • Combination therapy • Monotherapy • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

First-in-human study of ABBV-637, an EGFR-targeting BCL-XL–inhibiting antibody-drug conjugate combined with osimertinib (OSI) in relapsed/refractory, EGFR-mutated non-small cell lung cancer (NSCLC) (ESMO 2023) - P1 | "Conclusions ABBV-637 plus OSI showed clinical activity and a manageable safety profile in patients with RR NSCLC. Biomarker data suggest that response to ABBV-637 plus OSI may be enriched by excluding patients with targetable bypass mechanisms; ongoing research is needed to confirm association of mutation and patient selection."

P1 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • BCL2L1

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors (clinicaltrials.gov) - P1 | N=81 | Active, not recruiting | Sponsor: AbbVie | Trial completion date: Nov 2023 ➔ Feb 2024 | Trial primary completion date: Nov 2023 ➔ Feb 2024

Adverse events • Combination therapy • Monotherapy • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors (clinicaltrials.gov) - P1 | N=81 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting | Trial completion date: Nov 2026 ➔ Nov 2023 | Trial primary completion date: Nov 2026 ➔ Nov 2023

Adverse events • Combination therapy • Enrollment closed • Monotherapy • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

First-in-human phase I study of ABBV-637 as monotherapy and in combination in patients with relapsed and refractory solid tumors (ESMO 2022) - P1 | "This first-in-human trial evaluates the safety and efficacy of ABBV-637 as a monotherapy and in combination with docetaxel (DTX) or osimertinib (Osi) in patients (pts) with advanced or relapsed and refractory (RR) solid tumors. Enrollment for Parts 2/3 combination dose escalation began in January 2022. Table: 1185TiP"

Clinical • Monotherapy • P1 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • BCL2L1 • EGFR

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors (clinicaltrials.gov) - P1; N=109; Recruiting; Sponsor: AbbVie; Trial primary completion date: Nov 2025 ➔ Nov 2026

Adverse events • Combination therapy • Monotherapy • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors (clinicaltrials.gov) - P1; N=109; Recruiting; Sponsor: AbbVie; N=60 ➔ 109; Trial completion date: Nov 2025 ➔ Nov 2026

Adverse events • Clinical • Combination therapy • Enrollment change • Monotherapy • Trial completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors (clinicaltrials.gov) - P1; N=60; Not yet recruiting; Sponsor: AbbVie

Adverse events • Clinical • Combination therapy • Monotherapy • New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: AbbVie; Not yet recruiting ➔ Recruiting

Adverse events • Clinical • Combination therapy • Enrollment open • Monotherapy • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor